Bimatoprost
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Bimatoprost
- Molecular weight
- 415.57
- Structure (SMILES)
- CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
- bimatoprost
- Bimatoprost
- bimatoprost component of ganfort
- Bimatoprost component of ganfort
- durysta
- Durysta
- latisse
- Latisse
- lumigan
- Lumigan
- agn 192024
- AGN 192024
- AGN-192024
- agn192024
- AGN192024
- bimatoprost
- Bimatoprost
- Bimatoprost (Lumigan)
- Bimatoprost [EMA EPAR]
- Bimatoprost [INN]
- Bimatoprost [JAN]
- Bimatoprost [MART.]
- Bimatoprost [MI]
- Bimatoprost [ORANGE BOOK]
- Bimatoprost [USAN]
- Bimatoprost [VANDF]
- Bimatoprost [WHO-DD]
- bimatoprost ema epar
- bimatoprost inn
- bimatoprost jan
- bimatoprost mart
- bimatoprost mi
- Bimatoprost Ophthalmic
- bimatoprost ophthalmic solution
- Bimatoprost Ophthalmic Solution
And 19 more, listed on the interactive page.
- ATC classification codes
- S01EE03
Sources for recorded values
- CAS registry numbers
- 155206-00-1
- ChEMBL ID
- CHEMBL1200963
- InChIKey
- AQOKCDNYWBIDND-FTOWTWDKSA-N
- PubChem compound IDs
- 5311027
- RxNorm IDs (RxCUI)
- 283810
- FDA ingredient codes (UNII)
- QXS94885MZ
- Applicant
- ABBVIE
- Approval date
- 24 Dec 2008
- Application number
- NDA022369
- Status
- Authorised
- Status date
- 8 Mar 2002
- Authorisation date
- 8 Mar 2002
- Approved indications
- Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
- Product number
- EMEA/H/C/000391
- Authorisation holder
- AbbVie Deutschland GmbH & Co. KG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Glaucoma, Open-Angle
- Ocular Hypertension
European medicines record
- Patents
- 9
- Designations
- 1
- Earliest recorded loss of exclusivity
- 8 Jun 2036
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- bimatoprost
- Type
- Synthetic organic
- Drug name stem
- -prost
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Mechanism
- Prostanoid FP receptor agonist
- Action type
- Agonist
- Target
- Prostaglandin F2-alpha receptor
- Protein identifier
- P43088
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- FP receptor
- Gene symbol
- PTGFR
- Protein identifier
- P43088
- Median affinity
- 5.3
- Affinity units
- pIC50
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Prostanoid FP receptor agonist
- Action type
- Agonist
- Target
- Prostaglandin F2-alpha receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- PTGFR
- Protein identifier
- P43088
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Glaucoma, Open-Angle
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004190
- Subject identifier
- D005902
- Condition
- Alopecia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004191
- Subject identifier
- D000505
- Condition
- Alopecia Areata
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Vitiligo
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Ocular Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001069
- Subject identifier
- D009798
- Condition
- Graves Ophthalmopathy
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001466
- Subject identifier
- D049970
- Condition
- Hypotrichosis
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0003037
- Subject identifier
- D007039
- Condition
- Alopecia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004907
- Subject identifier
- D000505
- Condition
- Glaucoma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005041
- Subject identifier
- D005901
- Condition
- Hypotrichosis
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0018914
- Subject identifier
- D007039
- Condition identifier
- EFO_0004190
- Condition identifier
- EFO_0004191
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004192
- Condition identifier
- EFO_0004208
- Condition identifier
- EFO_1001069
- Condition identifier
- EFO_1001466
- Highest recorded phase
- 3
- Condition identifier
- HP_0002293
- Highest recorded phase
- 2
- Condition identifier
- HP_0010750
- Condition identifier
- HP_0010750
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001744
- Condition identifier
- MONDO_0003037
- Condition identifier
- MONDO_0003037
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004907
- Condition identifier
- MONDO_0004907
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0005041
- Condition identifier
- MONDO_0005041
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005129
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005338
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005339
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006875
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018914
And 2 more, listed on the interactive page.
- Event
- abdominal pain
- Reports
- 2
- Reporting signal score
- 51.7019
- Event
- abnormal sensation in eye
- Reports
- 25
- Reporting signal score
- 65.3483
- Event
- anaemia
- Reports
- 5
- Reporting signal score
- 44.1846
- Event
- arthralgia
- Reports
- 10
- Reporting signal score
- 51.9803
- Event
- asthenia
- Reports
- 16
- Reporting signal score
- 38.9271
- Event
- blepharal pigmentation
- Reports
- 42
- Reporting signal score
- 232.942
- Event
- blepharitis
- Reports
- 48
- Reporting signal score
- 147.54
- Event
- blepharopachynsis
- Reports
- 5
- Reporting signal score
- 29.6269
- Event
- condition aggravated
- Reports
- 7
- Reporting signal score
- 44.0372
- Event
- conjunctival hyperaemia
- Reports
- 24
- Reporting signal score
- 49.3527
- Event
- dark circles under eyes
- Reports
- 12
- Reporting signal score
- 37.8372
- Event
- decreased appetite
- Reports
- 4
- Reporting signal score
- 29.3977
- Event
- diarrhoea
- Reports
- 12
- Reporting signal score
- 105.02
- Event
- dizziness
- Reports
- 29
- Reporting signal score
- 41.2595
- Event
- drug interaction
- Reports
- 2
- Reporting signal score
- 47.4328
- Event
- dry eye
- Reports
- 100
- Reporting signal score
- 182.102
- Event
- dyspnoea
- Reports
- 28
- Reporting signal score
- 57.9147
- Event
- enophthalmos
- Reports
- 15
- Reporting signal score
- 69.0027
- Event
- erythema
- Reports
- 138
- Reporting signal score
- 76.8356
- Event
- erythema of eyelid
- Reports
- 322
- Reporting signal score
- 1,572.19
- Event
- eye colour change
- Reports
- 15
- Reporting signal score
- 51.1164
- Event
- eye discharge
- Reports
- 70
- Reporting signal score
- 197.902
- Event
- eye infection
- Reports
- 26
- Reporting signal score
- 41.2809
- Event
- eye inflammation
- Reports
- 20
- Reporting signal score
- 30.7362
- Event
- eye irritation
- Reports
- 494
- Reporting signal score
- 1,709.47
And 51 more, listed on the interactive page.
- NCT00273455
- NCT01217606
- NCT01243567
- NCT01464424
- NCT03927443
- NCT03966560
- NCT04890106
- NCT00300443
- NCT00332059
- NCT00332072
- NCT00332540
- NCT01271686
- NCT01655758
- NCT00347802
- NCT00347841
- NCT00348023
- NCT00348062
- NCT00486486
- NCT00705757
- NCT01426113
- NCT01448837
- NCT02154217
- NCT02390284
- NCT00907426
- NCT00958035
And 22 more, listed on the interactive page.
- Dose
- 1 drop
- Route
- Ophthalmic
- How often
- Once daily in the evening
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 4
- Polar surface area
- 89.79
- Calculated partition coefficient (ALogP)
- 3.15
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 12
- Heavy atoms
- 30
- Molecular formula
- C25H37NO4
- Monoisotopic mass
- 415.27225866
- Natural product
- Yes
- 0023-3205
- 0023-3616
- 0023-9652
- 0781-6206
- 42571-128
- 46708-507
- 46708-511
- 62332-507
- 62332-511
- 65862-802
- 68083-295
- 68083-296
- 68083-439
- 70069-401
- 70069-402
- 70069-403
- 70756-626
- 70756-627
- 70756-628
- 72266-139
- 72266-140
- 72266-241
- 81469-291
- 82584-010
- 60219-2149
And 3 more, listed on the interactive page.
- Recorded assays
- 93
- Active assays
- 2
- Confirmatory
- Other
- Antihypertensive Agents
Related records
Trials (140)
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
- 24-hour IOP-lowering Effect of 0.01% Bimatoprost
- A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
- A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study
- A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
- A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
- A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
- A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
- A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
- A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
- A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
- A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
- A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
- A Study of Bimatoprost 0.01% in the Clinical Setting
- A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
- A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Approved for (5)
- Glaucoma
- Hypotrichosis
- Hypotrichosis simplex
- Ocular hypertension
- Open-angle glaucoma
In development for (5)
- Alopecia Phase 2
- Alopecia areata Phase 1
- Androgenetic alopecia Phase 2
- Euthyroid Graves orbitopathy Phase 3
- Vitiligo Early phase 1
Other linked conditions (3)
- Alzheimer disease
- Cataract
- Hypertrichosis
Targets (1)
- PTGFR Prostanoid FP receptor agonist